The neuroepigenome, i.e., the epigenome of the nervous system, has become interesting for therapeutics in the last years due to widespread availability of dedicated drugs. A pivotal role for neuroepigenetics is certainly implied, both in physiology and pathology, by the highly dynamic structural and functional rearrangements that constantly occur into the nervous system, globally known as plasticity. Moreover, the idea that the pathophysiology of several neuropsychiatric disorders might involve epigenetic mechanisms is increasingly taking place due to accumulating experimental data and by the evidence of a synergistic interaction between genes and environment beneath most sporadic forms of these diseases. In this paper we will review the available evidence on the use of epigenome-modifying drugs in the field of neuropsychiatry, shortly describing for each disease the underlying assumptions of an epigenetic dysregulation. © 2014 Bentham Science Publishers.

Tremolizzo, L., RODRIGUEZ MENENDEZ, V., Conti, E., Zoia, C., Cavaletti, G., Ferrarese, C. (2014). Novel therapeutic targets in neuropsychiatric disorders: the neuroepigenome. CURRENT PHARMACEUTICAL DESIGN, 20(11), 1831-1839 [10.2174/13816128113199990535].

Novel therapeutic targets in neuropsychiatric disorders: the neuroepigenome

TREMOLIZZO, LUCIO;RODRIGUEZ MENENDEZ, VIRGINIA;CONTI, ELISA;ZOIA, CHIARA PAOLA;CAVALETTI, GUIDO ANGELO;FERRARESE, CARLO
2014

Abstract

The neuroepigenome, i.e., the epigenome of the nervous system, has become interesting for therapeutics in the last years due to widespread availability of dedicated drugs. A pivotal role for neuroepigenetics is certainly implied, both in physiology and pathology, by the highly dynamic structural and functional rearrangements that constantly occur into the nervous system, globally known as plasticity. Moreover, the idea that the pathophysiology of several neuropsychiatric disorders might involve epigenetic mechanisms is increasingly taking place due to accumulating experimental data and by the evidence of a synergistic interaction between genes and environment beneath most sporadic forms of these diseases. In this paper we will review the available evidence on the use of epigenome-modifying drugs in the field of neuropsychiatry, shortly describing for each disease the underlying assumptions of an epigenetic dysregulation. © 2014 Bentham Science Publishers.
Articolo in rivista - Review Essay
epigenetic, neuropsychiatric disorders, methylation
English
2014
20
11
1831
1839
none
Tremolizzo, L., RODRIGUEZ MENENDEZ, V., Conti, E., Zoia, C., Cavaletti, G., Ferrarese, C. (2014). Novel therapeutic targets in neuropsychiatric disorders: the neuroepigenome. CURRENT PHARMACEUTICAL DESIGN, 20(11), 1831-1839 [10.2174/13816128113199990535].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/44157
Citazioni
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
Social impact